MiddleBrook Pharmaceuticals, Inc. Reschedules Announcement of its Third Quarter 2007 Financial Results to November 14, 2007

GERMANTOWN, Md., Nov. 8 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. , a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced it has revised the date on which it will release results for the quarter ended September 30, 2007, to Wednesday, November 14, 2007, before the market opens. A full text copy of the release will be disseminated at that time and the Company's investor conference call will also be rescheduled to Wednesday, November 14, 2007.

In light of MiddleBrook's recent announcement to raise up to $10 million through its agreement with Deerfield Management, the Company has decided to postpone the announcement of its third quarter 2007 financial results until November 14, 2007. The Company had previously scheduled its third quarter 2007 financial results and conference call for Friday, November 9, 2007.

Edward M. Rudnic, Ph.D., president and chief executive officer, will host the Company's conference call to discuss the results and other corporate developments at 10:30 AM ET on Wednesday, November 14, 2007. Also participating on the call will be Robert C. Low, vice president, finance and CFO. The conference call dial-in numbers have not changed.

To participate in the conference call, dial the appropriate number below shortly before the 10:30 AM start time and ask for the MiddleBrook Pharmaceuticals conference call hosted by Dr. Rudnic.

The conference call will be broadcast simultaneously and archived on the Company's web site, www.middlebrookpharma.com. Investors should go to the web site at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Wednesday, November 14, 2007, beginning at 12:30 PM ET and will be accessible until Wednesday, November 21, 2007, at 5:00 PM ET. The replay call-in number is 1-800-642-1687 for domestic callers and 1-706-645-9291 for international callers. The access number is 23072308.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing a portfolio of anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front-loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). By examining the resistance patterns of bacteria and applying its delivery technologies, MiddleBrook has the potential to redefine infectious disease therapy and significantly improve drug efficacy, shorten length of therapy, and reduce drug resistance versus currently available antibacterial products. For more on MiddleBrook, please visit www.middlebrookpharma.com.

CONTACT: Bob Bannon, Vice President, Investor Relations & Corporate
Communications of MiddleBrook Pharmaceuticals, Inc., +1-301-944-6710,
rbannon@middlebrookpharma.com

Web site: http://www.middlebrookpharma.com/

Back to news